Sierra Oncology, Inc(NASDAQ:SRRA) 
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatm...
Website: http://www.sierraoncology.com
Founded: 2003
Full Time Employees: 69 (May 2021)
Sector: Healthcare
Industry: Biotechnology
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2022-01-03
P
O 21.86
H 22.59
L 21.38
C 21.80
V 46,738
10EMA 21.80
20EMA 21.80
60EMA 21.80
120EMA 21.80
250EMA 21.80